Key result
Angiotensin 1-7 restores VEGF-mediated angiogenesis and increases circulating progenitor cells in diabetic mice.
Why the study?
Does Angiotensin-(1-7) improve angiogenic function in the corpus cavernosum of mice with type 1 diabetes?
Does Angiotensin-(1-7) improve angiogenic function in the corpus cavernosum of mice with type 1 diabetes?
p-value: p=<0.02
Angiotensin-(1-7) reverses diabetes-induced angiogenic dysfunction in the corpus cavernosum by stimulating both the microvasculature and bone marrow-derived progenitor cells in a mouse model.
Hypothesis-generating for Ang-(1-7) in diabetic cavernosal vasculopathy; should not change practice pending human data.
INTRODUCTION: Angiotensin (Ang)-(1-7) is a recently identified vasoprotective heptapeptide, and it appears to activate the reparative functions of bone marrow-derived stem/progenitor cells (BMPCs). AIM: This study evaluated the effect of Ang-(1-7) in the angiogenic function of cavernosum in type 1 diabetes (T1D) and delineated the role of BMPCs in this protective function. METHODS: T1D was induced by streptozotocin in mice, and mice with 20-24 weeks of diabetes were used for the study. Ang-(1-7) was administered subcutaneously by using osmotic pumps. Cavernosa, and BMPCs from peripheral blood and bone marrow were evaluated in different assay systems. MAIN OUTCOME MEASURES: Angiogenic function was determined by endothelial tube formation in matrigel assay. Circulating BMPCs were enumerated by flow cytometry and proliferation was determined by BrdU incorporation. Cell-free supernatant of BMPCs were collected and tested for paracrine angiogenic effect. Expression of angiogenic factors in BMPCs and cavernosa were determined by real-time polymerase chain reaction. RESULTS: Ang-(1-7) (100 nM) stimulated angiogenesis in mouse cavernosum that was partially inhibited by Mas1 receptor antagonist, A779 (10 μM) (P < 0.05). In cavernosa of T1D, the angiogenic responses to Ang-(1-7) (P < 0.005) and VEGF (100 nM) (P < 0.03) were diminished. Ang-(1-7) treatment for 4 weeks reversed T1D-induced decrease in the VEGF-mediated angiogenesis. Ang-(1-7) treatment increased the circulating number of BMPCs and proliferation that were decreased in T1D (P < 0.02). Paracrine angiogenic function of BMPCs was reduced in diabetic BMPCs, which was reversed by Ang-(1-7). In diabetic BMPCs, SDF and angiopoietin-1 were upregulated by Ang-(1-7), and in cavernosum, VEGFR1, Tie-2, and SDF were upregulated and angiopoietin-2 was down-regulated. CONCLUSIONS: Ang-(1-7) stimulates angiogenic function of cavernosum in diabetes via its stimulating effects on both cavernosal microvasculature and BMPCs.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2014) studied Type 1 diabetes. Angiotensin-(1-7) vs. Diabetic control was evaluated on Angiogenic function and circulating bone marrow-derived stem/progenitor cells (p=<0.02). Angiotensin-(1-7) treatment for 4 weeks reversed type 1 diabetes-induced decreases in VEGF-mediated angiogenesis and increased circulating bone marrow-derived stem/progenitor cells (P<0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: